CONGERS, N.Y.—Aptar Pharma is nearing the completion of an expansion to its Congers facility, focused on providing injectable elastomeric component products for the pharmaceutical industry.
The firm said final construction is planned by the end of the first quarter of 2017. Aptar Pharma anticipates being able to ship validation batches to customers in the second quarter. The expansion is part of the firm's plan to increase its footprint in the U.S.
The added space will house state-of-the-art clean rooms and new equipment to perform automatic inspection of all parts during the finishing process to ensure product quality.
The facility designs and manufactures elastomeric closures—stoppers for vials, prefilled syringe and cartridge components such as plungers, needle shields and tip caps for all injectable pharmaceutical applications. The majority of the firm's formulations use pharmaceutical grades of halobutyl rubbers.
"This investment is continuing our commitment to growing and accelerating our footprint in North
America," Bas Van Buijtenen, president of Aptar Pharma's Injectables Division, said in a statement. "More significantly, the technology we are introducing will increase our ability to provide world-class manufacturing capabilities to our customers locally. This will provide premium products, shorter lead-times and more responsive service for the US elastomeric components markets."
Aptar Pharma is one of three divisions of AptarGroup Inc., a leading global supplier of a range of dispensing solutions for the beauty, personal care, home car, prescription drug, consumer health car, injectables, food, and beverage markets. The firm is headquartered in Crystal Lake, Ill., with facilities North America, Europe, Asia and South America.